drugset / Trial / NCT00893737

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737

Phase 4 Completed 147 enrolled Cady, Roger, M.D. GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

Many clinical trials may not fully explore criteria that are important to some migraine patients' definition of "complete response." This study offers the opportunity to evaluate the effectiveness of Treximet™ when non-standard criteria are examined (for example, neck pain, irritability or fatigue). Subjects enrolled at 8 investigative sites will complete 2 visits. Subjects will complete a Completeness of Response Survey at Visit 1 considering their usual migraine medication (a triptan) and a Completeness of Response Survey at Visit 2 considering their study medication (Treximet™).

Timeline

Start
2009-06
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg
Subject Sumatriptan Unknown 85 mg

Indications